Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.49 |
| ▸ | AKT2 | P31751 | 1/20 | 0.49 |
| ▸ | HTR7 | P34969 | 4/20 | 0.46 |
| ▸ | HTR1A | P08908 | 2/20 | 0.44 |
| ▸ | IKBKB | O14920 | 2/20 | 0.38 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 2/20 | 0.38 |
| ▸ | DRD3 | P35462 | 2/20 | 0.38 |
| ▸ | DRD1 | P21728 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | DRD5 | P21918 | 1/20 | 0.38 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.37 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.37 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3340562 | 0.91 | DRD2 (0.49) | CHEK1AKT2HTR7HTR1ADRD2 | |
| SCHEMBL3338619 | 0.86 | HTR7 (0.62) | CHEK1AKT2HTR7HTR1AIKBKB | |
| SCHEMBL3338065 | 0.81 | AKT2 (0.54) | CHEK1AKT2HTR7HTR1AIKBKB | |
| SCHEMBL3341215 | 0.79 | HTR7 (0.71) | HTR7HTR1ADRD2DRD3DRD1 | |
| SCHEMBL3338676 | 0.78 | CHEK1 (0.51) | CHEK1AKT2HTR7HTR1AIKBKB | |
| SCHEMBL3339883 | 0.76 | BRD4 (0.53) | HTR7HTR1ACREBBPBRD4 | |
| SCHEMBL3338906 | 0.75 | HTR7 (0.77) | HTR7HTR1ACREBBPBRD4 | |
| SCHEMBL3341529 | 0.72 | HTR7 (0.74) | HTR7HTR1ADRD3BCHE | |
| SCHEMBL13035810 | 0.72 | AKT2 (0.67) | CHEK1AKT2IKBKBIKBKEACVR1 | |
| SCHEMBL13212504 | 0.70 | TAAR1 (0.55) | HTR7HTR1ADRD2DRD3DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013189588-A1 | HETEROCYCLYL-SUBSTITUTED-PHENYL DERIVATIVES FOR THE TREATMENT OF ERECTILE DYSFUNCTION | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2013-12-27 | — | — | WO | claimed |
| EP-2676954-A1 | Heterocyclyl-substituted-phenyl derivatives as vasodilators | Laboratorios del Dr. Esteve S.A. (ES) | 2013-12-25 | — | — | EP | claimed |
| US-20100197717-A1 | COMBINATION OF A 5HT7 RECEPTOR LIGAND AND AN OPIOID RECEPTOR LIGAND | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-08-05 | — | — | US | claimed |
| US-20100152252-A1 | Heterocyclyl-substituted-ethylamino-phenyl derivatives, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE,S.A. (ES) | 2010-06-17 | — | — | US | claimed |
| EP-2148674-A1 | COMBINATION OF A 5HT7 RECEPTOR LIGAND AND AN OPIOID RECEPTOR LIGAND | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2010-02-03 | — | — | EP | claimed |
| EP-2114894-A1 | HETEROCYCLYL-SUBSTITUTED-EHYLAMINO-PHENYL DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-11-11 | — | — | EP | claimed |
| WO-2008145335-A1 | COMBINATION OF A 5HT7 RECEPTOR LIGAND AND AN OPIOID RECEPTOR LIGAND | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-12-04 | — | — | WO | claimed |
| EP-1997493-A1 | Combination of a 5-HT7 receptor ligand and an opioid receptor ligand | Laboratorios del Dr. Esteve S.A. (ES) | 2008-12-03 | — | — | EP | claimed |
| EP-1997807-A1 | Heterocyclyl-substituted-ethylamino-phenyl derivatives, their preparation and use as medicaments | Laboratorios del Dr. Esteve S.A. (ES) | 2008-12-03 | — | — | EP | claimed |
| WO-2008077625-A1 | HETEROCYCLYL-SUBSTITUTED-EHYLAMINO-PHENYL DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-07-03 | — | — | WO | claimed |
| EP-1935886-A1 | Heterocyclyl-substituted-ethylamino-phenyl derivatives, their preparation and use as medicaments | Laboratorios del Dr. Esteve S.A. (ES) | 2008-06-25 | — | — | EP | claimed |
| WO-2013189588-A1 | HETEROCYCLYL-SUBSTITUTED-PHENYL DERIVATIVES FOR THE TREATMENT OF ERECTILE DYSFUNCTION | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2013-12-27 | — | — | WO | disclosed |
| EP-2676954-A1 | Heterocyclyl-substituted-phenyl derivatives as vasodilators | Laboratorios del Dr. Esteve S.A. (ES) | 2013-12-25 | — | — | EP | disclosed |
| US-20100197717-A1 | COMBINATION OF A 5HT7 RECEPTOR LIGAND AND AN OPIOID RECEPTOR LIGAND | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-08-05 | — | — | US | disclosed |
| US-20100197717-A1 | COMBINATION OF A 5HT7 RECEPTOR LIGAND AND AN OPIOID RECEPTOR LIGAND | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-08-05 | — | — | US | disclosed |
| EP-1997493-A1 | Combination of a 5-HT7 receptor ligand and an opioid receptor ligand | Laboratorios del Dr. Esteve S.A. (ES) | 2008-12-03 | — | — | EP | disclosed |
| EP-1997493-A1 | Combination of a 5-HT7 receptor ligand and an opioid receptor ligand | Laboratorios del Dr. Esteve S.A. (ES) | 2008-12-03 | — | — | EP | disclosed |
| WO-2008077625-A1 | HETEROCYCLYL-SUBSTITUTED-EHYLAMINO-PHENYL DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-07-03 | — | — | WO | disclosed |
| EP-1935886-A1 | Heterocyclyl-substituted-ethylamino-phenyl derivatives, their preparation and use as medicaments | Laboratorios del Dr. Esteve S.A. (ES) | 2008-06-25 | — | — | EP | disclosed |
| EP-1935886-A1 | Heterocyclyl-substituted-ethylamino-phenyl derivatives, their preparation and use as medicaments | Laboratorios del Dr. Esteve S.A. (ES) | 2008-06-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197717-A1 | COMBINATION OF A 5HT7 RECEPTOR LIGAND AND AN OPIOID RECEPTOR LIGAND | OPRL1, OPRM1, OPRK1 | CHEK1 4688/4885AKT2 4606/4885HTR7 5/4885 |
| US-20100152252-A1 | Heterocyclyl-substituted-ethylamino-phenyl derivatives, their preparation and use as medicaments | PKM, PKLR, HNMT | CHEK1 2634/4885AKT2 3617/4885HTR7 630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.